EN DE

ShareHope Medicine Co (8403) Fair Value & Analysis

Healthcare · TW · Market cap 2.7B TWD

SM ShareHope Medicine Co 8403 · TWO
Price19.10 TWD
Fair Value21.22 TWD
Upside+11.1%
Quality50/100
Watch ShareHope Medicine Co for free, get notified when fair value or trend changes. Watch for free
Weak Growth
Thin margins · 2.9% net margin
Low debt · generates free cash flow
Trails peers (4/14)
Narrow moat 26/100
Evidence: Medium Range 15.81 TWD – 26.64 TWD Share as image

Fair value as of: Jul 23, 2026

From 23 valuation models · updated 18 days ago

Share price −1.0% over the past month.

A solid business, screening 11% undervalued on our models.

What matters now

  • Our model range runs from 15.81 TWD (bear) to 26.64 TWD (bull), base 21.22 TWD. The closer the price sits to the lower half, the larger the margin of safety.
  • Quality 50/100 (solid quality) with medium evidence: read the verdict with care.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

45.30 TWD 18.85 TWD Fair Value 21.22 TWD Mar 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 23, 2026.

How to read this chart

60‑month range 18.85 TWD – 45.30 TWD · fair‑value band 15.81 TWD – 26.64 TWD · the 19.10 TWD price screens below the 21.22 TWD fair value. Dashed = 300-day average. As of Jul 23, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

ShareHope Medicine Co (8403) currently trades at 19.10 TWD, while our model-based Fair Value estimate is 21.22 TWD, implying the stock looks roughly 11.1% undervalued today. The Quality Score stands at 50/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.

Over the trailing twelve months, ShareHope Medicine Co generated revenue of 4.4B TWD at a net margin of 2.9%. Revenue grew 2.4% year over year. It earns a return on equity of 2.7%. Net debt stands at 58.3M TWD. Fundamentals as of Jul 23, 2026

Our scenario range runs from 15.81 TWD (bear case) to 26.64 TWD (bull case); at 19.10 TWD, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 31% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 2% fair-value upside, at 11%, 8403 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF 21.20 TWD 27.41 TWD 35.44 TWD 80
Residual Income 18.41 TWD 18.17 TWD 16.15 TWD 76
Rev-Margin DCF 16.96 TWD 22.83 TWD 29.09 TWD 74
All 23 models by family
DCF Models
FCF DCF 20.73 TWD 27.38 TWD 36.33 TWD 38
Owner Earnings 24.07 TWD 32.03 TWD 42.76 TWD 31
5Y Revenue Exit 16.96 TWD 22.56 TWD 29.32 TWD 39
5Y EBITDA Exit 28.54 TWD 42.95 TWD 58.93 TWD 41
5Y P/E Exit 19.43 TWD 26.92 TWD 34.25 TWD 38
10Y Revenue Exit 17.96 TWD 23.13 TWD 29.26 TWD 36
10Y EBITDA Exit 25.33 TWD 36.52 TWD 50.14 TWD 37
10Y P/E Exit 19.78 TWD 25.99 TWD 32.73 TWD 35
Earnings-Based
Graham-Dodd 7.00 TWD 15.32 TWD 19.52 TWD 54
PEG = 1.0 2.42 TWD 3.46 TWD 4.50 TWD 46
EPV 11.86 TWD 13.13 TWD 14.22 TWD 59
Multiples
P/E Multiple 16.99 TWD 22.65 TWD 28.32 TWD 63
P/S Multiple 13.13 TWD 17.50 TWD 21.88 TWD 58
P/B Multiple 13.13 TWD 17.50 TWD 21.88 TWD 55
EV/EBIT 20.07 TWD 25.48 TWD 30.89 TWD 53
EV/EBITDA 37.67 TWD 48.95 TWD 60.23 TWD 54
EV/Revenue 15.42 TWD 20.38 TWD 25.35 TWD 43
Asset-Based
NCAV (Graham) 12.51 TWD 16.76 TWD 25.02 TWD 50
Growth DCF
Growth DCF 21.20 TWD 27.41 TWD 35.44 TWD 80
Rev-Margin DCF 16.96 TWD 22.83 TWD 29.09 TWD 74
Economic Profit
Residual Income 18.41 TWD 18.17 TWD 16.15 TWD 76
ROIC Compounder 11.86 TWD 13.13 TWD 14.22 TWD 72
Growth Earnings
Growth-Adj P/E 12.57 TWD 17.96 TWD 23.35 TWD 68

Widest divergence: DCF Models (26.92 TWD) versus Earnings-Based (13.13 TWD). Highest evidence: Growth DCF (80).

Notify me when 8403 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) 4.4B TWD
Revenue growth (YoY) +2.4%
Net margin 2.9%
Return on equity 2.7%
Free cash flow 232M TWD FY2025
P/E ratio 18.9
More key figures
Operating margin 1.8%
EPS (TTM) 1.03 TWD
EPS growth (YoY) -42.5%
Net debt 58.3M TWD FY2024

Figures from reported company fundamentals · as of Jul 23, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 50/100

Of which business quality 51 · Market factors (momentum, volatility) 37

Profitability 29
Margins and returns on capital today
Quality Growth 38
Are margins and returns improving?
Cashflow 55
Earnings quality: real cash, not paper profit
Fin. Strength 57
Balance sheet, leverage, solvency risk
Investment 98
Disciplined investing over empire-building
Low Volatility 100
Calm price path (market factor)
Momentum 16
Price trend over the last 3–12 months (market factor)
52W Momentum 1
Distance to the 52-week high (market factor)
Net Issuance 43
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

ShareHope Medicine Co., Ltd. provides integrated medical services in Taiwan. The company is involved in health management and operation activities; human resource dispatch of professional medical staff services.

Full company description

ShareHope Medicine Co., Ltd. provides integrated medical services in Taiwan. The company is involved in health management and operation activities; human resource dispatch of professional medical staff services. It also offers provision of medical, pharmaceutical, and health devices, as well as long-distance health care services; and rental of medical devices. ShareHope Medicine Co., Ltd. was founded in 2003 and is based in Taoyuan City, Taiwan.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

ShareHope Medicine Co reported revenue of 4.4B TWD in FY2025 versus 3.9B TWD in FY2021, a compound +3.1%/yr. Reported net income was 142M TWD in FY2025, compounding −11.7%/yr from FY2021.

Growth Quality 40/100
Revenue growth is weak, negative or inconsistent.
Latest Revenue (FY 2025)
4.4B TWD
Latest YoY
+0.7%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+1.7%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+1.2%
Avg. growth/yr (8Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+6.6%
Revenue +3.1%/yr
FY21 3.9B TWD
FY22 4.1B TWD
FY23 3.9B TWD
FY24 4.3B TWD
FY25 4.4B TWD
Net income −11.7%/yr
FY21 233M TWD
FY22 294M TWD
FY23 125M TWD
FY24 200M TWD
FY25 142M TWD

Watch 8403: get an alert when its fair value changes →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "ShareHope Medicine Co Fair Value". https://www.fairvalue-calculator.com/stock/8403

Peer Group

Medical Distribution · 81 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 50 · Below median
Fair Value upside +11% · Above median
Return on equity (TTM) 3% · Below median
Return on assets 1% · Below median
Net margin (TTM) 3% · Above median
Operating margin (TTM) 2% · Below median
Revenue growth 2% · Below median
Dividend yield (TTM) 0.0% · Bottom 25%
Debt / equity 0.24× · Higher than median

Valuation Multiples vs Medical Distribution median · lower = cheaper

P/E (TTM) 18.9× · Pricier than median
P/B 0.78× · Cheaper than median
P/S (TTM) 0.61× · Pricier than median
P/FCF 0.4× · Cheaper than 75% of peers
EV/EBITDA 6.4× · Pricier than median

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 48 · sector 32
FUTURE 12 · sector 14
PAST 11 · sector 21
HEALTH 88 · sector 97
DIVIDEND 0 · sector 53

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Jul 23, 2026).

Stock Price Fair Value vs Fair Value
McKesson Corporation MCK $805.96 $819.31 +2%
Cencora, Inc COR $303.44 $175.74 -42%
Cardinal Health, Inc CAH $224.94 $141.77 -37%
Henry Schein, Inc HSIC $87.82 $74.67 -15%
Shanghai Pharmaceuticals Holding 601607 ¥16.70 ¥33.96 +103%
Sinopharm Group 1099 HK$16.74 HK$61.33 +266%
Galenica AG GALE CHF 87.05 CHF 61.79 -29%
Guangzhou Baiyunshan Pharmaceutical Holdings 600332 ¥21.50 ¥28.65 +33%
Jointown Pharmaceutical Group 600998 ¥4.99 ¥9.84 +97%
Asker Healthcare Group ASKER kr 79.45 kr 25.69 -68%

Compare ShareHope Medicine Co with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is ShareHope Medicine Co (8403) overvalued or undervalued?
As of Jul 23, 2026, our model estimates a fair value of 21.22 TWD versus a price of 19.10 TWD, about +11% (undervalued).
What is the fair value of 8403?
Our model-based fair value for ShareHope Medicine Co is 21.22 TWD (as of Jul 23, 2026), built from audited fundamentals. The current price is 19.10 TWD.
What is the quality score of 8403?
ShareHope Medicine Co has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of ShareHope Medicine Co (8403)?
ShareHope Medicine Co reported trailing-twelve-month revenue of about 4.4B TWD (latest available figure, as of Jul 23, 2026).
What is the net profit margin of 8403?
The net profit margin of ShareHope Medicine Co is about 2.9%, meaning it keeps roughly 2.9% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track ShareHope Medicine Co and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.